Interactive Breakout Discussions

Join your colleagues and fellow delegates for a focused, informal discussion moderated by a member of our speaking faculty.  A small group format allows participants to meet potential collaborators, share examples from their own work and discuss ideas with peers.

TUESDAY, 16 MARCH, 12.05pm - 12.25pm

Automation and Digitization for Process Development
Alan Baines, Director, Project Lead Testing Solutions, Lonza BioScience Solutions
Rob Lutskus, Associate Director, Lonza Global Informatics

  • Productivity increases – data from aseptic sampling and automation case studies
  • Improved data quality from automated sampling and automated data capture
  • Quality and data integrity improvements from electronic batch records
  • Automated data collection and removal of redundancies with paperless systems

Optimizing biopharma downstream processes: Enhance efficiencies and cost-effectively in downstream production
Willie Hesselink, Senior Technical Application Project Manager, Biopharma Production, Avantor

  • Fields of improvement in DSP
  • Chances and Challenges of Digitalization
  • Current chromatography technologies
  • Raw material handling strategies
  • Process improvements in small-scale and big-scale manufacturing

WEDNESDAY, 17 MARCH, 10.15am - 10.45am

Technologies for the Future of Bioprocess Development: What Are They and How to Choose?
Moritz von Stosch, PhD, Chief Innovation Officer, Datahow, Switzerland

  • What are the bioprocess (development) technologies of the future?​
  • How to focus effort on the most relevant technologies for bioprocess (development) of the future?
  • Will our current business models still work?
  • How do new modalities change the bioprocess (development) landscape?

DSP, Process Intensification and Digitalization
Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)

  • Common DSP challenges
  • Integrated continuous manufacturing
  • Process control
  • Digitalization

Gene Therapy CMC and Manufacturing
Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd.
Florence Salmon, PhD, Independent Consultant, Former, Director Regulatory Affairs CMC, Novartis Pharma AG

  • Common Analytical Challenges for Viral Vectors
  • Potency Assay Development
  • Process Development and Scale-up
  • Process Change and Comparability

Optimising Formulation Development for Novel Modalities, High and Low Concentration Protein Formulations, Combination Products and Co-Formulations
Paul Dalby, PhD, Professor, Biochemical Engineering, University College London, United Kingdom

  • Rapid formulation of novel formats, eg. mRNA, viral vectors, exosomes
  • New directions with established modalities, eg. mAbs
  • Analytical advances and challenges
  • How to handle the very low concentration products